LLY in “China Becomes Pharma's Global R&D Engine”
Eli Lilly and Company
Lilly can supplement its internal pipeline at attractive speed and cost through deals such as its acquisition of ex-China rights to Hengrui's investigational incretin program.
LLY impact map — “China Becomes Pharma's Global R&D Engine”
How this story travels from the headline to LLY’s own business — positive, negative or mixed, direct or indirect, the mechanism, and how strong the exposure is.
Loading LLY impact map…
Price history, marked with story events
Oct 8, 2025 – Oct 9, 2026 · 250 sessions
Prices updated during market hours · refreshed about every 30 minutes while the market is open · delayed data, not for trading decisions
Numbered markers tie price moves to earnings, trial or study results, management comments and analyst or demand data. Loading events…
Full story
China Becomes Pharma's Global R&D Engine
Western drugmakers are licensing clinically validated Chinese molecules rather than relying solely on expensive in-house discovery.
BULL side — Lilly can supplement its internal pipeline at attractive speed and cost through deals such as its acquisition of ex-China rights to Hengrui's investigational incretin program.
Read the full China Becomes Pharma's Global R&D Engine storyBull side
2 stories- GLP-1 Eats Everything
LLY in “GLP-1 Eats Everything”
FadingExposure: not rated yetAppetite suppression as a macro variable.
Supply-constrained franchise with pricing power.
- Viewing
LLY in “China Becomes Pharma's Global R&D Engine”
FadingExposure: not rated yetWestern drugmakers are licensing clinically validated Chinese molecules rather than relying solely on expensive in-house discovery.
Lilly can supplement its internal pipeline at attractive speed and cost through deals such as its acquisition of ex-China rights to Hengrui's investigational incretin program.
Bear side
1 story- America Imports the World's Drug Prices
LLY in “America Imports the World's Drug Prices”
StableExposure: not rated yetUS reference pricing puts global blockbuster economics—and not just American list prices—under pressure.
Its premium-priced, high-growth drug portfolio has substantial earnings sensitivity to lower US benchmark prices.